Fixed drug combinations for the acute treatment of migraine: Place in therapy

CNS Drugs

Volumn 19, Issue 9, 2005, Pages 769-784

  Loder, Elizabeth ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; BARBITURIC ACID DERIVATIVE; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CAFERGOT; CAFFEINE; DEXTROPROPOXYPHENE PLUS ASPIRIN PLUS PHENAZONE; DEXTROPROPOXYPHENE PLUS ASPIRIN PLUS PHENAZONE PLUS PHENTIAZIN CARBOXYL CHLORIDE PLUS CAFFEINE; DOLERON; DOMPERAMOL; ERGOTAMINE DERIVATIVE; EXCEDRIN; EXCEDRIN MIGRAINE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; INDOMETHACIN PLUS PROCHLORPERAZINE PLUS CAFFEINE; ISOMETHEPTENE; ISOMETHEPTENE MUCATE; METOCLOPRAMIDE; MIDRID; MIGRALEVE; MIGRAMAX; MIGRAVESS; MIGRIL; MIGWELL; NAPROXEN PLUS SUMATRIPTAN; NAPROXEN SODIUM PLUS METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PARACETAMOL PLUS CODEINE; PARACETAMOL PLUS CODEINE PLUS BUCLIZINE; PARACETAMOL PLUS TRAMADOL; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN SUCCINATE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; WIGRAINE;

ACUTE DRUG ADMINISTRATION; AEROSOL; CLINICAL TRIAL; DIFMETRE; DIGESTIVE SYSTEM FUNCTION DISORDER; DOLERON NOVUM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; INJECTION; MIGRAINE; NAUSEA; NOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SUPPOSITORY; SYSTEMATIC REVIEW; TABLET; VOMITING;

ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARBITURATES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY; ERGOTAMINE; HUMANS; METHYLAMINES; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS;

EID: 24944479046     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519090-00004     Document Type: Review

References (58)

1. Oates LN, Scholz MJ, Hoffert MJ. Polypharmacy in a headache centre population. Headache 1993; 33: 436-8
2. Putnam GP, O'Quinn S, Bolden-Watson CP, et al. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 1999; 19 (7): 668-75
3. Subcutaneous Sumatriptan International Study Group. The treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21
4. Raffa J. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther 2001; 26 (4): 257-64
5. Desmeules J, Rollason V, Piguet V, et al. Clinical pharmacology and rationale of analgesic combinations. Eur J Anaesthesiol 2003; 20 Suppl. 28: 7-11
6. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002; 4: 343-9
7. Prusinski A. Monotherapy or polytherapy in migraine. Neuroepidemiology 1987; 6 (4): 186-9
8. Krymchantowski AV. Acute treatment of migraine: breaking the paradigm of monotherapy. BMC Neurol 2004; 4 (1): 4
9. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 1998; 38: 18-22
10. McLean W, Boucher EA, Brennan M. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Can J Clin Pharmacol 2000; 7: 191-7
11. Goldstein J, Gawel MJ, Winner P, et al. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache 1998; 38 (7): 516-22
12. Boureau F, Joubert JM, Laswerre V, et al. Double-blind comparison of acetaminophen 400mg/codeine 25mg combination versus aspirin 1000mg and placebo in acute migraine attacks. Cephalalgia 1994; 14 (2): 156-61
13. Gawel MJ, Szalai JF, Stiglick A, et al. Evaluation of analgesic agents in recurring headache compared with other clinical pain models. Clin Pharm Ther 1990; 47 (4): 504-8
14. Uzogara E, Sheehan DV, Manschreck R, et al. A combination drug treatment for acute common migraine. Headache 1986; 26: 231-6
15. Scopa J, Jorgensen PB, Foster JB. Migraleve in the prophylaxis of migraine. Curr Ther Res Clin Exp 1974; 16 (12): 1270-5
16. Jorgensen PB, Weightman D, Foster JB. Comparison of migraleve and buclizine in prophylaxis of migraine. Curr Ther Res Clin Exp 1974; 16 (12): 1276-80
17. Carasso RL, Yehuda S. The prevention and treatment of migraine with an analgesic combination. Br J Clin Pract 1984; 38: 25-7
18. Adam EI. A treatment for the acute migraine attack. J Int Med Res 1987; 15 (2): 71-5
19. The General Practitioners Research Group. Migraine treated with an antihistamine-analgesic compound. Practitioner 1973; 211: 357-61
20. Somerville BW. Treatment of migraine attacks with an analgesic combination (Mersyndol). Med J Aust 1976; 23: 865-6
21. Hakkarainen H, Gustafsson B, Stockman O. A comparative trial of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache 1978; 18 (1): 35-9
22. Hakkarainen H, Quiding H, Stockman O. Mild analgesics as an alternative to ergotamine in migraine: a comparative trial with acetylsalicylic acid, ergotamine tartrate, and a dextropropoxyphene compound. J Clin Pharmacol 1980; 20 (10): 590-5
23. Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: naproxen sodium versus ergotamine plus caffeine. Headache 1988; 28 (4): 263-6
24. Kinnunen E, Erkinjuntti T, Fakkila M, et al. Placebo-controlled, double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia 1988; 8 (3): 175-9
25. Pradalier A, Rancurel G, Dordain G, et al. Acute attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia 1985; 5 (2): 107-13
26. Ostfeld AM. A study of migraine pharmacotherapy. Am J Med Sci 1961; 241: 192-8
27. Ryan RE. Double-blind clinical evaluation of the efficacy and safety of ergostin-caffeine, ergotamine-caffeine and placebo in migraine headache. Headache 1970; 9 (4): 212-20
28. Friedman AP, DiSerio FJ, Hwang DS. Symptomatic relief of migraine: multicenter comparison of Cafergot-P-B, Cafergot, and placebo. Clin Ther 1989; 11: 170-82
29. Hirt D, Lataste X, Taylor P. A comparison of DHE nasal spray and cafergot in acute migraine. Cephalalgia 1989; 9 Suppl. 10: 410-1
30. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991; 31 (5): 314-22
31. Le Jeunne C, Gomez JP, Pradalier A, et al. Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Eur Neurol 1999; 41 (1): 37-43
32. Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in actue treatment of migraine: a multicentre, randomized, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47 (2): 99-107
33. Christie S, Gobel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10mg versus ergotamine/caffeine in migraine. Eur Neurol 2003; 49 (1): 20-9
34. Stieg RL. Double-blind study of belladonna-ergotamine-phenobarbitol for treatment of recurrent throbbing headache. Headache 1977; 17: 120-4
35. Yuill GM, Swinburn WR, Liversedge LA. A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. Br J Clin Pract 1972; 26: 76-9
36. Dowson A, Ball K, Haworth D. Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50mg in moderate to severe migraine: a randomized UK primary care study. Curr Med Res Opin 2000; 16 (3): 190-7
37. Tokola RA, Kangasniemi P, Neuvonen PJ, et al. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984; 4 (4): 253-63
38. Hakkarainen H, Parantainen J, Gothoni G, et al. Tolfenamic acid and caffeine: a useful combination in migraine. Cephalalgia 1982; 2 (4): 173-7
39. Hakkarainen H, Vapaatalo H, Gothoni G, et al. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984; 4 (4): 253-63
40. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984; 4 (2): 107-11
41. DiMonda V, Nicolodi M, Aloisio A, et al. Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache 2003; 43 (8): 835-44
42. Dexter SC, Graham AN, Johnston E, et al. Double-blind, cross-over study of paramax in the acute treatment of common and classical migraine. Br J Clin Pract 1989; 39 (10): 398-2
43. Hugues FC, Lacoste JP, Joire JE. Repeated doses of combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine. Headache 1997; 37 (7): 452-4
44. Chabriat H, Joire JE, Danchot J, et al. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 1994; 14: 297-300
45. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923-6
46. Lipton RB, Stewart RF, Ryan Jr RE, et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55 (2): 210-7
47. Ryan RE. A study of midrin in the symptomatic relief of migraine headache. Headache 1974; 14 (1): 33-42
48. Behan PO. Isometheptene compound in the treatment of vascular headache. Practitioner 1978; 221: 937-9
49. Ogden HD. Controlled studies of a new agent in vascular headache. Headache 1963; 3 (1): 29-31
50. Diamond S. Treatment of migraine with isometheptene, acetaminophen and dichloralphenozone combination: a double blind, crossover trial. Headache 1976; 15 (4): 282-7
51. Diamond S, Medina JL. Isometheptene: a non-ergot drug in the treatment of migraine. Headache 1975; 15 (3): 211-3
52. Freitag FO, Cady R, DiSerio F, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 2001; 41: 391-8
53. Silberstein SD, Freitag FG, Rozen TD, et al. Tramadol HCL/acetaminophen versus placebo in the treatment of acute migraine pain [abstract]. Headache 2004; 44 (5): 464
54. Making sense of migraine treatments: bandolier meta-analysis [online]. Available from URL: http://www.jr2ox.ac.uk/bandolier/band591b59-2.html [Accessed 2005 Jun 28]
55. Pozen announces receipt of not-approvable letter for MT 100 [online]. Available from URL: http://www.pozen.com/product/mt100.asp [Accessed 2004 Aug 24]
56. Sellers EM, Hoornweg K, Busto UE, et al. Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Can J Clin Pharmacol 1999; 6: 18-25
57. Bigal ME. Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep 2003; 7 (1): 55-62
58. Trexima™. Pozen Pharmaceutical Development Company [press release, online.] Available from URL: http:// www.pozen.com/product/trexima.asp [Accessed 2004 Aug 24]